ES2533242T3 - Prevención y tratamiento de afecciones oculares asociadas con el complemento - Google Patents

Prevención y tratamiento de afecciones oculares asociadas con el complemento Download PDF

Info

Publication number
ES2533242T3
ES2533242T3 ES08756130.4T ES08756130T ES2533242T3 ES 2533242 T3 ES2533242 T3 ES 2533242T3 ES 08756130 T ES08756130 T ES 08756130T ES 2533242 T3 ES2533242 T3 ES 2533242T3
Authority
ES
Spain
Prior art keywords
antibody
complement
prevention
binding fragment
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08756130.4T
Other languages
English (en)
Spanish (es)
Inventor
Philip Hass
Yin Jianping
Kenneth Katschke Jr.
Micah Steffek
Christian Wiesmann
Menno Van Lookeren Campagne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2533242(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2533242T3 publication Critical patent/ES2533242T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
ES08756130.4T 2007-05-23 2008-05-22 Prevención y tratamiento de afecciones oculares asociadas con el complemento Active ES2533242T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
US939791P 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Publications (1)

Publication Number Publication Date
ES2533242T3 true ES2533242T3 (es) 2015-04-08

Family

ID=39638868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08756130.4T Active ES2533242T3 (es) 2007-05-23 2008-05-22 Prevención y tratamiento de afecciones oculares asociadas con el complemento

Country Status (28)

Country Link
US (6) US8007791B2 (en:Method)
EP (1) EP2152755B1 (en:Method)
JP (4) JP5416695B2 (en:Method)
KR (1) KR101540126B1 (en:Method)
CN (3) CN101754980B (en:Method)
AR (1) AR066660A1 (en:Method)
AU (1) AU2008256835B2 (en:Method)
BR (1) BRPI0811142A8 (en:Method)
CA (1) CA2683498A1 (en:Method)
CL (1) CL2008001498A1 (en:Method)
CY (1) CY1116062T1 (en:Method)
DK (1) DK2152755T3 (en:Method)
ES (1) ES2533242T3 (en:Method)
HK (1) HK1207327A1 (en:Method)
HR (1) HRP20150281T1 (en:Method)
IL (2) IL201476A (en:Method)
MX (1) MX2009012422A (en:Method)
PE (1) PE20090294A1 (en:Method)
PH (1) PH12013500992B1 (en:Method)
PL (1) PL2152755T3 (en:Method)
PT (1) PT2152755E (en:Method)
RS (1) RS53901B1 (en:Method)
RU (2) RU2522976C2 (en:Method)
SG (1) SG10201401404RA (en:Method)
SI (1) SI2152755T1 (en:Method)
TW (2) TW201417829A (en:Method)
WO (1) WO2008147883A1 (en:Method)
ZA (1) ZA200907028B (en:Method)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE412185T1 (de) * 2000-04-29 2008-11-15 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
MX337061B (es) 2005-11-04 2016-02-11 Genentech Inc Uso de inhibidores de la via del complemento para tratar enfermedades oculares.
EP3466971A1 (en) * 2006-11-02 2019-04-10 Genentech, Inc. Humanized anti-factor d antibodies and uses thereof
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CA2735779A1 (en) * 2008-09-02 2010-03-11 Matthew Burger Bicyclic kinase inhibitors
EP2391419B1 (en) 2009-01-29 2019-06-12 ForSight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
EP3960134A1 (en) 2010-08-05 2022-03-02 ForSight Vision4, Inc. Implantable therapeutic device
RU2593954C2 (ru) * 2010-11-01 2016-08-10 Дженентек, Инк. Прогнозирование прогрессирования возрастной макулодистрофии до поздней стадии с помощью полигенного показателя
MX347391B (es) 2011-01-04 2017-04-25 Novartis Ag Compuestos de indol o análogos de los mismos útiles para el tratamiento de degeneración macular relacionada con la edad (amd).
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
CN104619698B (zh) 2012-06-28 2016-08-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
JP6238980B2 (ja) 2012-07-12 2017-11-29 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
EP3381943B1 (en) 2012-07-25 2022-03-16 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
WO2014160884A1 (en) 2013-03-28 2014-10-02 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
EP3054965B1 (en) * 2013-10-07 2021-04-14 Massachusetts Eye & Ear Infirmary Anti-factor d antibody for use in preventing or reducing retinal detachment
AU2014339890A1 (en) * 2013-10-25 2016-06-02 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
US10179821B2 (en) 2014-05-01 2019-01-15 Genentech, Inc. Anti-factor D antibodies
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
IL258030B (en) * 2015-09-23 2022-08-01 Sangamo Therapeutics Inc Htt suppressing factors and their uses
WO2017075170A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Methods of measuring factor d activity and potency of factor d inhibitors
EP3368074A2 (en) * 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
WO2017075252A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
RU2021117293A (ru) 2015-10-30 2021-06-23 Дженентек, Инк. АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
IL260182B2 (en) * 2015-12-23 2023-12-01 eleva GmbH Polypeptides for inhibiting complement activation
CA3011819A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
JP2020507581A (ja) * 2017-02-10 2020-03-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗ｄ因子抗体及びその使用
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
EP3999626A4 (en) * 2019-07-18 2023-11-22 Pandorum Technologies Private Limited PROCESSES FOR CULTURE OF STEM CELLS TO OBTAIN PRODUCTS AND THEIR MODES OF PRODUCTION

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000053758A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
DK1481990T3 (da) 1997-11-21 2007-10-01 Genentech Inc A33-beslægtede antigener og deres farmakologiske anvendelser
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
KR100425965B1 (ko) 1998-02-20 2004-04-06 타녹스 인코퍼레이티드 보체 활성화의 억제물질
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
EP1141285A2 (en) 1998-12-16 2001-10-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6383484B1 (en) * 1998-12-21 2002-05-07 Ludwig Institute For Cancer Research Antibodies to truncated VEGF-D and thereof
EP1141284A2 (en) 1998-12-22 2001-10-10 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
CZ303128B6 (cs) 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
WO2001036102A1 (en) 1999-11-02 2001-05-25 Uliyanovsky Gosudarstvenny Tekhnichesky Universitet Method for cleaning liquids of ferromagnetic particles and device for the implementation thereof
CA2388777A1 (en) 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 18 human secreted proteins
EP1666494A1 (en) 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
EP1309685A2 (en) 2000-07-20 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
MX337061B (es) 2005-11-04 2016-02-11 Genentech Inc Uso de inhibidores de la via del complemento para tratar enfermedades oculares.
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
EP3466971A1 (en) * 2006-11-02 2019-04-10 Genentech, Inc. Humanized anti-factor d antibodies and uses thereof
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
HK1207327A1 (en) 2016-01-29
EP2152755A1 (en) 2010-02-17
US20180079826A1 (en) 2018-03-22
BRPI0811142A8 (pt) 2018-12-18
TW200904471A (en) 2009-02-01
KR101540126B1 (ko) 2015-07-28
RU2522976C2 (ru) 2014-07-20
CN104367999A (zh) 2015-02-25
JP2010528047A (ja) 2010-08-19
TW201417829A (zh) 2014-05-16
RU2009147744A (ru) 2011-06-27
JP2017197577A (ja) 2017-11-02
AU2008256835A1 (en) 2008-12-04
IL201476A (en) 2016-11-30
JP2016145205A (ja) 2016-08-12
US20130302333A1 (en) 2013-11-14
CN107096029A (zh) 2017-08-29
MX2009012422A (es) 2009-12-04
CY1116062T1 (el) 2017-02-08
RS53901B1 (sr) 2015-08-31
IL248552A0 (en) 2016-12-29
PH12013500992B1 (en) 2018-12-14
PE20090294A1 (es) 2009-03-27
HK1139161A1 (en) 2010-09-10
US8497094B2 (en) 2013-07-30
CN101754980A (zh) 2010-06-23
JP5416695B2 (ja) 2014-02-12
WO2008147883A1 (en) 2008-12-04
TWI419704B (zh) 2013-12-21
US8007791B2 (en) 2011-08-30
EP2152755B1 (en) 2014-12-31
US8268310B2 (en) 2012-09-18
DK2152755T3 (en) 2015-03-02
PL2152755T3 (pl) 2015-06-30
SI2152755T1 (sl) 2015-05-29
CL2008001498A1 (es) 2009-06-12
PT2152755E (pt) 2015-04-01
IL201476A0 (en) 2010-05-31
SG10201401404RA (en) 2014-08-28
CN101754980B (zh) 2014-10-29
JP2014087346A (ja) 2014-05-15
ZA200907028B (en) 2010-12-29
PH12013500992A1 (en) 2016-01-25
US20110282034A1 (en) 2011-11-17
RU2014113046A (ru) 2015-10-10
AR066660A1 (es) 2009-09-02
HRP20150281T1 (hr) 2015-04-10
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
CN107096029B (zh) 2021-02-26
US20130052685A1 (en) 2013-02-28
US20090181017A1 (en) 2009-07-16
WO2008147883A8 (en) 2013-05-23
US20160272726A1 (en) 2016-09-22
KR20100033973A (ko) 2010-03-31
CA2683498A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
ES2533242T3 (es) Prevención y tratamiento de afecciones oculares asociadas con el complemento
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
AR123876A2 (es) Composición farmacéutica de anticuerpos anti-cgrp
CL2012000518A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de mieloma en un mamífero (div. sol. 3615-07).
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CO6700829A2 (es) Moduladores novedosos y métodos de uso
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
PE20120816A1 (es) Composiciones que comprenden anticuerpos de dickkopf-1
GT200800098A (es) Anticuerpos anti mn y metodos para su utilización
AR099812A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
PE20121129A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
PE20121361A1 (es) Antagonistas de pcsk9
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
EA201070888A1 (ru) Антитела и их производные
PE20161152A1 (es) Anticuerpos y metodos de uso
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
PE20211708A1 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r